The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis.

Abstract

Targeting regulatory T cells (Treg cells) with interleukin-2 (IL-2) constitutes a novel therapeutic approach for autoimmunity. As anti-cancer therapy with IL-2 has revealed substantial toxicities a mutated human IL-2 molecule, termed AIC284 (formerly BAY 50-4798), has been developed to reduce these side effects. To assess whether AIC284 is efficacious in autoimmunity, we studied its therapeutic potential in an animal model for Multiple Sclerosis. Treatment of Lewis rats with AIC284 increased Treg cell numbers and protected the rats from Experimental Autoimmune Encephalomyelitis (EAE). AIC284 might, thus, also efficiently prevent progression of autoimmune diseases in humans.

• Authors: Andreas Weishaupt, Daniela Paulsen, Sandra Werner, Nelli Wolf, Gabriele Köllner, Helga Rübsamen-Schaeff, Thomas Hünig, Thomas Kerkau, Niklas Beyersdorf
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 282 Pg. 63-72 (May 15 2015) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 25903730 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier B.V. All rights reserved.

Chemical References

• Annexin A5
• Antigens, CD
• Antineoplastic Agents
• Interleukin-2
• Recombinant Proteins
• aldesleukin

Topics

• Animals
• Annexin A5 (metabolism)
• Antigens, CD (metabolism)
• Antineoplastic Agents (therapeutic use)
• Autoimmunity (drug effects)
• Cells, Cultured
• Coculture Techniques
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Female
• Flow Cytometry
• Interleukin-2 (analogs & derivatives, pharmacology, therapeutic use)
• Killer Cells, Natural (drug effects)
• Multiple Sclerosis (immunology, pathology, prevention & control)
• Pulmonary Edema (etiology, prevention & control)
• Rats
• Rats, Inbred Lew
• Recombinant Proteins (therapeutic use)
• T-Lymphocytes, Regulatory (drug effects)